EW vs OMCL: fair value comparison
Edwards Lifesciences Corporation and Omnicell, Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, EW currently sits closer to the top of our discount ranking. EW carries the stronger quality grade.
| EW | OMCL | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $90.21 | $37.65 |
| 12-month range | $81.26–$88.82 | $29.96–$48.70 |
| Sector rank | #49 of 113 Healthcare | #52 of 113 Healthcare |
| Quality grade | A | D |
| Leverage | Low | Low |
| Margin trend | Stable | — |
| Revenue growth | Modest | — |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | — | Downtrend |
| 52-week position | The top quarter | The lower-middle quarter |
Full single-stock breakdowns: EW fair value analysis · OMCL fair value analysis